Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $70.37 USD
Change Today -1.32 / -1.84%
Volume 526.2K
CRL On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

charles river laboratories (CRL) Snapshot

Open
$71.30
Previous Close
$71.69
Day High
$71.83
Day Low
$70.12
52 Week High
03/20/15 - $84.69
52 Week Low
07/11/14 - $52.02
Market Cap
3.3B
Average Volume 10 Days
359.1K
EPS TTM
$2.92
Shares Outstanding
47.4M
EX-Date
--
P/E TM
24.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHARLES RIVER LABORATORIES (CRL)

charles river laboratories (CRL) Related Bloomberg News

View More Bloomberg News

charles river laboratories (CRL) Related Businessweek News

No Related Businessweek News Found

charles river laboratories (CRL) Details

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist its clients in supporting the use of research models in drug discovery and development comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target within a cell through delivery of clinical drug candidates; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides non-animal or in vitro methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and specific pathogen free fertile chicken eggs and chickens for the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

7,900 Employees
Last Reported Date: 02/17/15
Founded in 1947

charles river laboratories (CRL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Corporate Executi...
Total Annual Compensation: $530.3K
Corporate Executive Vice President and Presid...
Total Annual Compensation: $524.9K
Chief Scientific officer and Corporate Execut...
Total Annual Compensation: $518.1K
Chief Administrative Officer, General Counsel...
Total Annual Compensation: $587.5K
Compensation as of Fiscal Year 2014.

charles river laboratories (CRL) Key Developments

Charles River Laboratories International, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 10:00 AM

Charles River Laboratories International, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Charles River Laboratories International, Inc. Expands Revolving Credit Facility

Charles River Laboratories International, Inc. has expand the revolving credit facility to provide additional capacity for general corporate purposes, including acquisitions. The new facility includes a $400 million U.S. term loan and a revolver of up to $900 million, a portion of which can be drawn in foreign currencies. The drawn amounts in the new facility were $361.8 million on the revolver, denominated in U.S. dollars, euros and British pounds and the full $400 million on the term loan. These amounts are similar to the balances on former credit facility at the end of the first quarter.

Charles River Laboratories International Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 28, 2015; Reaffirms Earnings Guidance for the Fiscal Year 2015

Charles River Laboratories International, Inc. announced unaudited consolidated earnings results for the first quarter ended March 28, 2015. For the first quarter, the company’s total revenue from continuing operations was $320.414 million, an increase of 7.0% from $299.368 million in the first quarter of 2014. Operating income was $43.005 million against $39.706 million a year ago. Income from continuing operations before income taxes was $31.952 million against $42.986 million a year ago. Income from continuing operations, net of income taxes was $31.621 million or $0.66 per diluted share against $32.628 million or $0.67 per diluted share a year ago. Net income attributable to common shareholders was $31.541 million or $0.66 per diluted share against $32.232 million or $0.67 per diluted share a year ago. Net cash provided by operating activities was $11.252 million against $28.463 million a year ago. Capital expenditures were $10.648 million against $11.190 million a year ago. Operating income, excluding specified charges (Non-GAAP) was $51.815 million against $50.981 million a year ago. Net income from continuing operations attributable to common shareholders, excluding specified charges (Non-GAAP) was $37.601 million or $0.79 per diluted share against $39.275 million or $0.82 per diluted share a year ago. The decline was attributable to a significantly smaller gain from its limited partnership investments, which was $0.02 per share in the first quarter of 2015, compared to a $0.08 per share for the same period in 2014. In addition, foreign currency translation reduced earnings per share by approximately $0.03 in the first quarter. Free cash flow declined to $0.6 million in the first quarter of 2015 from $17.3 million last year. This significant decline was primarily driven by 2 large items that reduced operating cash flow in the quarter: First, performance-based cash bonus payments were approximately higher than last year due to the company's outperformance in 2014. This was previously included in free cash flow guidance for 2015; the second item was related to the timing of cash inflows and outflows associated with certain tax items. Timing reduced operating cash flow by approximately $7 million in the first quarter, but is expected to normalize over the course of the year and will not have a meaningful impact for the full year. For the fiscal year 2015, the company is updating its forward-looking guidance based on continuing operations for 2015, which was originally provided on February 10, 2015. Revenue growth is now expected to be 6.5% to 8.0% on a constant-currency basis, primarily due to expected stronger Safety Assessment revenue. Based on current rates, the company expects foreign currency translation will reduce revenue growth by approximately 5.5%, which would result in reported revenue growth of 1.0% to 2.5%. The company originally estimated a 5.0% impact from foreign currency translation and reported revenue growth of 1.0% to 2.5%. The company’s outlook for earnings per share in 2015 is unchanged, as: GAAP EPS from continuing operations estimate to be in the range of $3.15 - $3.25, amortization of intangible assets per share to be $0.31, operating losses per share to be $0.04, Non-GAAP EPS estimate to be in the range of $3.55 - $3.65. The company continue to expect net interest expense to be in a range of $12 million to $14 million in 2015. This outlook primarily reflects an expectation that LIBOR rates will begin to edge higher later in the year. Because of normal quarterly fluctuations based on the earnings mix throughout the year, the company remain comfortable with non-GAAP tax rate outlook of 27% to 28% for the year. The company remain on track to achieve free cash flow of $195 million to $205 million in 2015. CapEx outlook for the year continues to be approximately $70 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRL:US $70.37 USD -1.32

CRL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioanalytical Systems Inc $2.02 USD +0.0199
Ergomed PLC 178.00 GBp 0.00
PAREXEL International Corp $64.00 USD -1.85
Quintiles Transnational Holdings Inc $72.08 USD -1.17
WuXi PharmaTech Cayman Inc $41.45 USD -1.48
View Industry Companies
 

Industry Analysis

CRL

Industry Average

Valuation CRL Industry Range
Price/Earnings 26.7x
Price/Sales 2.5x
Price/Book 5.1x
Price/Cash Flow 22.2x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHARLES RIVER LABORATORIES, please visit www.criver.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.